| Patents for C12P 21 - Preparation of peptides or proteins (112,499) |
|---|
| 04/22/2004 | WO2002092782A3 Diagnosis and treatment of malignant neoplasms |
| 04/22/2004 | WO2002090300A8 Nucleic acids and proteins with thioredoxin reductase activity |
| 04/22/2004 | WO2002064731A9 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 04/22/2004 | WO1991007986A8 Method of treating septic shock |
| 04/22/2004 | WO1990013281A3 Method of suppressing hiv infection |
| 04/22/2004 | US20040078835 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 04/22/2004 | US20040078833 Mutations in and genomic structure of herg - along QT syndrome gene |
| 04/22/2004 | US20040077844 Spheres are functionalized in a controlled manner to enable covalent linkages of ligands |
| 04/22/2004 | US20040077842 First antigen recognition portion that binds a C3b-like receptor and a second that binds an antigenic molecule present in the circulatory system |
| 04/22/2004 | US20040077840 Methods for isolating molecular mimetics of unique Neisseria meningitidis serogroups B epitopes |
| 04/22/2004 | US20040077837 Microtubule-associated proteins and tubulins |
| 04/22/2004 | US20040077678 Urea substituted imidazoquinoline ethers |
| 04/22/2004 | US20040077532 Aglyco products and methods of use |
| 04/22/2004 | US20040077069 Method for the production of a heterologous protein by a fungus |
| 04/22/2004 | US20040077064 Identification and isolation of novel DNA and to the recombinant production of novel polypeptides |
| 04/22/2004 | US20040077051 LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications |
| 04/22/2004 | US20040077049 For preventing, ameliorating, disorders or diseases including cancer, peripheral and central nervous system disorders, genitourinary disorders, cardiovascular disorders, and Chronic obstructive pulmonary (or airways) disease (COPD) |
| 04/22/2004 | US20040077047 Allows efficient production of heterologous protein and wherein any contamination of the product protein by vegetative spores is avoided |
| 04/22/2004 | US20040077046 Histone deacetylase-related gene and protein |
| 04/22/2004 | US20040077045 Melanoma Associated antigen (MAGE) tumor associated genes, nucleic acids encoding such peptides and antibodies relating thereto; Human Leukocyte Antigen (HLA) |
| 04/22/2004 | US20040077042 Cell line expressing mutated human tissue-type plasminogen activator, the constructing strategy thereof and method of preparing expressed protein |
| 04/22/2004 | US20040077037 Regiospecific modification of peptides and proteins with probes and reporter molecules using peptidases in combination with a non-amino acid- like or non-peptide-like substrate mimetic |
| 04/22/2004 | US20040077029 Human protooncogene and protein encoded therein |
| 04/22/2004 | US20040077021 Haptens, intermediates, and immunogens that are useful in the production of antibodies specific for the methylenedioxy class of amphetamine derivatives |
| 04/22/2004 | US20040077013 DNA constructs, host cells and production methods for the expression and recovery of polypeptides altered to have glycosylation sites added or deleted; employ a DNA segment corresponding to a mammalian tissue plasminogen activator |
| 04/22/2004 | US20040077007 Human SMN-like protein |
| 04/22/2004 | US20040077000 Using cynomologous monkey P-glycoprotein nucleic acids and polypeptides in determining bioavailability of drugs and for screening for inhibitors of cynomologous P-glycoprotein |
| 04/22/2004 | US20040076991 Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity |
| 04/22/2004 | US20040076985 Reagents which regulate human chemokine-like receptor and reagents which bind to human chemokine-like receptor gene products, useful in preventing, ameliorating, or correcting dysfunctions or diseases including HIV infection, |
| 04/22/2004 | US20040076951 Also antibodies, gene chips, transgenic non-human animals |
| 04/22/2004 | US20040076631 Treating infections caused by respiratory syncytial virus, transfected eukaryotic cells, isolating human B cells from transfected mouse, use for immunoassay, diagnosis the virus, test kits |
| 04/22/2004 | US20040076627 Humanised antibodies |
| 04/22/2004 | US20040076625 A fusion proteins comprising self or non-self antigens, is used for treatment and prevention of immunoglobulin E related diseases, gene expression |
| 04/22/2004 | US20040076607 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 04/22/2004 | CA2823937A1 Hiv vaccine formulations |
| 04/22/2004 | CA2501855A1 Nucleic acids encoding duramycin |
| 04/22/2004 | CA2501635A1 Method of purifying lantibiotics |
| 04/22/2004 | CA2501476A1 Hiv vaccine formulations |
| 04/22/2004 | CA2501459A1 Production of homotrimeric fusion proteins |
| 04/22/2004 | CA2500901A1 Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
| 04/22/2004 | CA2499081A1 Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment |
| 04/21/2004 | EP1411131A1 Process for producing template dna and process for producing protein in cell-free protein synthesis system with the use of the same |
| 04/21/2004 | EP1411124A2 Human cancer antigen of tyrosinase-related protein 1 and 2 and genes encoding same |
| 04/21/2004 | EP1411116A1 PEPTIDE SYNTHASE GENE, PEPTIDE SYNTHASE AND PROCESS FOR PRODUCING DIPEPTIDE |
| 04/21/2004 | EP1411064A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours |
| 04/21/2004 | EP1411062A1 Process for producing dipeptide,peptide synthase to be used therein and process for producing peptide synthase |
| 04/21/2004 | EP1411060A1 PROCESS FOR PRODUCING DIPEPTIDE, L−AMINO ACID AMIDE HYDROLASE TO BE USED THEREIN AND PROCESS FOR PRODUCING L−AMINO ACID AMIDE HYDROLASE |
| 04/21/2004 | EP1410807A1 Methods and compositions useful for inhibition of angiogenesis |
| 04/21/2004 | EP1410035A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 04/21/2004 | EP1410023A2 Methods using o?6 -alkylguanine-dna alkyltransferases |
| 04/21/2004 | EP1410013A2 Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer |
| 04/21/2004 | EP1409718A2 Canine toxicity genes |
| 04/21/2004 | EP1409713A1 ASSAY FOR MEASURING FACTOR VIIa-ANTITHROMBIN COMPLEXES |
| 04/21/2004 | EP1409709A2 A method for improving recombinant protein stability and solubility |
| 04/21/2004 | EP1409695A2 Expression system for recombinant proteins |
| 04/21/2004 | EP1409694A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 04/21/2004 | EP1409692A1 Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine |
| 04/21/2004 | EP1409684A1 Novel surface exposed immunoglobulin d-binding protein from moraxella catarrhalis |
| 04/21/2004 | EP1409680A2 Novel human proton-gated channels |
| 04/21/2004 | EP1409677A2 Receptors and membrane-associated proteins |
| 04/21/2004 | EP1409675A1 Gene involved in apoptosis regulation |
| 04/21/2004 | EP1409673A2 Human leucine-rich repeat containing protein, expressed predominantely in small intestine, hlrrsi1 |
| 04/21/2004 | EP1409655A2 Immunoglobulin superfamily proteins |
| 04/21/2004 | EP1409550A1 Extracellular messengers |
| 04/21/2004 | EP1409549A2 Compositions and methods for the diagnosis and treatment of tumor |
| 04/21/2004 | EP1409546A2 Protease inhibitor conjugates and antibodies useful in immunoassay |
| 04/21/2004 | EP1409544A2 Human dr4 antibodies and uses thereof |
| 04/21/2004 | EP1409535A2 Human secreted proteins |
| 04/21/2004 | EP1409532A2 Moringa seed proteins |
| 04/21/2004 | EP1409531A2 Heterocarpine, a human ghrh-binding protein |
| 04/21/2004 | EP1409523A2 Pancam nucleic acids and polypeptides |
| 04/21/2004 | EP1409018A2 Stable lyophilized pharmaceutical formulation of igg antibodies |
| 04/21/2004 | EP1409016A2 Antibodies to opgl |
| 04/21/2004 | EP1408909A2 Improved conditionally replicating vectors for inhibiting viral infections |
| 04/21/2004 | EP1408908A2 Compositions and methods for inhibition of cancer invasion and angiogenesis |
| 04/21/2004 | EP1232396B1 Assay of isomerised and/or optically inverted proteins |
| 04/21/2004 | EP1191707B1 Power amplifier sharing in a wireless communication system with transmit diversity |
| 04/21/2004 | EP1141019B1 Substance for producing highly effective anti-tumour medicaments and corresponding method |
| 04/21/2004 | EP1007065B1 Preparation of collagen |
| 04/21/2004 | EP0836647B1 Antiviral proteins, dna coding sequences therefor, and uses thereof |
| 04/21/2004 | EP0714406B1 Refolding of polypeptides like recombinant insulin-like growth factor igf-i |
| 04/21/2004 | EP0641215B1 Protease-resistant thrombomodulin analogs |
| 04/21/2004 | CN1491281A Neurotonin and use thereof |
| 04/21/2004 | CN1491278A Lipase variants |
| 04/21/2004 | CN1491232A Modified leptin with reduced immunogenicity |
| 04/21/2004 | CN1491231A Modified keratinocyte growth factor (KGF) with reduced immunogenicity |
| 04/21/2004 | CN1491116A Hepatitis B virus treatment |
| 04/21/2004 | CN1490409A Preparing method for recombinant chBJSTWO protein and use thereof |
| 04/21/2004 | CN1490332A Recombinant human IA-2 antigen preparing method |
| 04/21/2004 | CN1490056A Immune method and composition for HIV-1 |
| 04/21/2004 | CN1490049A CD26/DPP IV application for medicine in preparing treatment and/or diagnostic disease |
| 04/21/2004 | CN1146667C Process for extracting amino acid polypeptide with animal bone marrow and tissue |
| 04/21/2004 | CN1146664C Fusion polypeptides comprising and IgE-binding domain and HSA component, and their diagnostic and therapeutic uses |
| 04/21/2004 | CN1146576C Proteins from mammaliam liver and their use in oncology |
| 04/21/2004 | CN1146442C Lympha toxin-alpha/beta compositions as anti tumor agent and antilympha toxin beta receptor antibody |
| 04/21/2004 | CN1146441C Composition of containing lympha toxin beta receptor |
| 04/21/2004 | CN1146440C Vascular endothelial growth factor-B |
| 04/20/2004 | US6723893 Mice having a mutant SOD-1-encoding transgene |
| 04/20/2004 | US6723841 Corticotropin-releasing factor2 receptors |
| 04/20/2004 | US6723833 Improved polypeptides, including antibodies, which not only don't exhibit the ?deactivating? event of aspartyl isomerization, but also display equal to or better than affinity to the target molecule (e.g., antigen) |